The leader of Gilead’s Kite Pharma is sure that anito-cel, the biotech’s next-generation multiple myeloma CAR-T challenger to Carvykti, is ready for prime time—and that the company is ready to bring ...

With dosing underway in a pivotal phase 3 trial, Star Therapeutics is illuminating the clinical potential of its anti-bleeding antibody VGA039. | With dosing underway in a pivotal phase 3 trial, Star ...

Pfizer’s VC arm has backed a $100 million series A raise for OTR Therapeutics, as the Chinese biotech tacks on preclinical ...

Freenome is taking itself public via a special purpose acquisition company, also known as a SPAC deal, to help raise funds in ...

The industry’s mRNA alliance is demanding steady FDA leadership, warning that the current “unprecedented turmoil” at the ...

All this data builds Jefferies’ argument: the FDA change could help boost return on investment and therefore drive R&D spend.

“SCN2A and SCN8A DEEs are devastating conditions with extremely high mortality due to the debilitating seizure burden they ...

Natera is looking to grow its portfolio of tools to detect the recurrence of cancer with a deal to acquire Foresight ...

The outside advisors analyzed the results of the RELIEVE-HF pivotal trial, which randomized 508 patients to either receive ...

In 105 boys and young men enrolled in the HOPE-3 trial, patients given deramiocel every three months for a year had 54% ...

Almost four years after penning its first amyloidosis collaboration with Neurimmune, AstraZeneca has returned to ...

Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech ...